Disease · MONDO_0005192
Comparisons in its trials73
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 73
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bevacizumab + Gemcitabine + Erlotinib vs Placebo + Gemcitabine + Erlotinib: serious adverse events | 139 of 297 | 119 of 286 | 583 | NCT01214720 | Trial comparisons |
| Erlotinib vs Placebo: Number of Participants With Adverse Events (AEs) | 90 of 104 | 71 of 103 | 207 | NCT00674973 | Trial comparisons |
| Erlotinib vs Placebo: serious adverse events | 21 of 104 | 11 of 103 | 207 | NCT00674973 | Trial comparisons |
| Dasatinib + GEM vs Placebo + GEM: serious adverse events | 53 of 98 | 48 of 101 | 199 | NCT01395017 | Trial comparisons |
| Erlotinib, Gemcitabine: Rash Grade < 2 vs Erlotinib, Gemcitabine: Rash Grade ≥ 2: Number of Participants Who Died at 6 Months | 69 of 115 | 8 of 38 | 153 | NCT00461708 | Trial comparisons |
| Erlotinib, Gemcitabine: Rash Grade < 2 vs Erlotinib, Gemcitabine: Rash Grade ≥ 2: Number of Participants With Disease Progression or Death | 110 of 115 | 33 of 38 | 153 | NCT00461708 | Trial comparisons |
| Erlotinib, Gemcitabine: Rash Grade < 2 vs Erlotinib, Gemcitabine: Rash Grade ≥ 2: Number of Participants Who Died During the Study | 102 of 115 | 27 of 38 | 153 | NCT00461708 | Trial comparisons |
| Erlotinib, Gemcitabine: Rash Grade < 2 vs Erlotinib, Gemcitabine: Rash Grade ≥ 2: serious adverse events | 58 of 115 | 14 of 38 | 153 | NCT00461708 | Trial comparisons |
| MORAb-009 Plus Gemcitabine ('MORAb-009') vs Placebo Plus Gemcitabine ('Placebo'): serious adverse events | 49 of 73 | 54 of 75 | 148 | NCT00570713 | Trial comparisons |
| Arm A (Nab-Paclitaxel + Gemcitabine) vs Arm B (Gemcitabine): deaths from any cause | 5 of 72 | 11 of 74 | 146 | NCT02106884 | Trial comparisons |
| Arm A (Nab-Paclitaxel + Gemcitabine) vs Arm B (Gemcitabine): serious adverse events | 50 of 72 | 48 of 74 | 146 | NCT02106884 | Trial comparisons |
| OGX-427 vs Placebo: serious adverse events | 64 of 64 | 63 of 63 | 127 | NCT01844817 | Trial comparisons |
| AMG 820 1100 MG vs AMG 820 1400 MG: deaths from any cause | 12 of 98 | 1 of 18 | 116 | NCT02713529 | Trial comparisons |
| AMG 820 1100 MG vs AMG 820 1400 MG: serious adverse events | 70 of 98 | 10 of 18 | 116 | NCT02713529 | Trial comparisons |
| Apricoxib/Gemcitabine/Erlotinib vs Placebo/Gemcitabine/Erlotinib: serious adverse events | 16 of 70 | 5 of 39 | 109 | NCT00709826 | Trial comparisons |
| Zilovertamab Vedotin Q1/3W vs Zilovertamab Vedotin Q2/3W: Number of Participants Who Experienced an Adverse Event (AE) | 70 of 70 | 32 of 32 | 102 | NCT04504916 | Trial comparisons |
| Zilovertamab Vedotin Q1/3W vs Zilovertamab Vedotin Q2/3W: Number of Participants Who Discontinued Study Treatment Due to an AE | 7 of 70 | 6 of 32 | 102 | NCT04504916 | Trial comparisons |
| Zilovertamab Vedotin Q1/3W vs Zilovertamab Vedotin Q2/3W: deaths from any cause | 54 of 70 | 18 of 32 | 102 | NCT04504916 | Trial comparisons |
| Zilovertamab Vedotin Q1/3W vs Zilovertamab Vedotin Q2/3W: serious adverse events | 29 of 70 | 16 of 32 | 102 | NCT04504916 | Trial comparisons |
| Arm A: Irinotecan/Docetaxel vs Arm B: Irinotecan/Docetaxel/Cetuximab: serious adverse events | 35 of 46 | 36 of 45 | 91 | NCT00042939 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005192/comparisons